{"metadata": {"organization_names": [], "person_names_verified": [], "organization_names_verified": ["pharmaceutical product development inc", "pharmaceutical product development", "pii compound information"], "topics": [], "entities_rejected": [], "person_names": [], "agreement_id": "aad7a2e31a0e369a1ea67d6ab841877a70af22c28e7237cf522e3d1c103cdfa7", "vars": {"Party": {"PHARMACO INVESTMENTS, INC.": "[[Party 1]]", "RANBAXY LABORATORIES LTD.": "[[Party 3]]", "a wholly owned subsidiary of Pharmaceutical Product Development, Inc.": "[[Party 2]]"}}, "terms": ["**      [*", "** (expressly excluding any requirement to complete any **", "** (other than **", "** (\u201cMajor Regulatory Filings\u201d) for a Licensed Product for the Indication as promptly as practicable. In executing the Development Plan, PII shall be solely responsible for all costs and expenses relating to the Development Plan and obtaining Regulatory Approval for the Licensed Product(s). Without limiting the generality of the foregoing, PII shall be responsible for the preparation, filing and prosecution of all agency applications for obtaining Regulatory Approvals in the Territory which are required to commercially sell or use the Licensed Product(s) in the Territory and for all subsequent related submissions. All Regulatory Documentation and Regulatory Approvals in the Territory shall be owned and filed in the name of PII. PII shall use Diligent Efforts in preparing the Major Regulatory Filings for Regulatory Approval of the Licensed Product(s) and in causing such agency applications to progress through the Regulatory Approval process. PII shall use Diligent Efforts for the preparation and submission of all governmental and agency applications for Regulatory Approval for a Licensed Product for the Indication in countries of the Territory other than **", "** are performed using different comparitors and/or patient populations, the Milestone Payment under this Section 5.02(a) shall be triggered upon the Completion of the last arm of such **", "** are performed using different comparitors and/or patient populations, the Milestone Payment under this Section 5.02(b) shall be triggered upon the Completion of **", "** identified as **", "** indication. Notwithstanding the foregoing or anything to the contrary contained in this Agreement, in the event PII pursues the Development of the Compound (whether in a single or combination product) for the treatment of **", "** other than the Compound and the Licensed Product(s) hereunder, or **", "** percent (**", "** relating to such **", "** shall occur upon the Completion of the **", "**% to the Party controlling the enforcement action and **", "**) relating to such **", "*****", "***] Confidential treatment requested; certain information omitted and filed separately with the SEC. contemplated in the Development Plan, then Completion of the **", "**, provided that (i) such services are limited to those that are usual and customary for clinical research organizations in general, and PII and its Affiliates in particular; and (ii) PII and its Affiliates shall not retain (1) any right, title, interest or license in any such **", "**. At the time RBX decides to exercise its co-marketing rights, RBX may send to PII a written request to discuss the possibility of RBX **", "**. For clarity, if **", "**. In the event multiple arms of a **", "**.**", "**Amendment.**", "**Arbitration.**", "**Assignability.**", "**Audit.**", "**Authorized Disclosure.**", "**Books and Records.**", "**Clinical Milestone Payments.**", "**Counterparts.**", "**DEVELOPMENT PLAN**", "**Date**", "**Development Reports.**", "**Development; Regulatory Activities and Approvals.**", "**Dollars.**", "**Early Termination by PII**", "**Employee Agreements.**", "**Entire Agreement.**", "**Exclusivity**", "**Exercise of Option.**", "**Force Majeure.**", "**Foreign Payments.**", "**General Principle**", "**Governing Law.**", "**Headings.**", "**Indemnification.**", "**Infringement of Patent Rights.**", "**Jointly Prepared.**", "**Launch and Marketing.**", "**License Fee.**", "**License Option.**", "**License Terms**", "**License to RBX Intellectual Property**", "**Limitations on Publications.**", "**Manufacturing**", "**Material Breach.**", "**Method of Calculation.**", "**Milestone**", "**No Third Party Beneficiary**", "**Nondisclosure of Confidential Information.**", "**Notices.**", "**Notification.**", "**OPTION AND LICENSE AGREEMENT**", "**Option Covenants.**", "**Ownership of PII Information.**", "**Ownership of Patents.**", "**PPD Guarantee.**", "**Patent Marking.**", "**Patent Prosecution.**", "**Payments to Third Parties.**", "**Product Recalls and Insurance**", "**RBX Co-Marketing Rights.**", "**RBX Know-How**", "**RBX PATENTS**", "**Relationship of the Parties.**", "**Release of Information.**", "**Remaining Licensed Product.**", "**Residual Obligation upon Termination.**", "**Right to Sublicense.**", "**Rights of RBX Upon Early Termination.**", "**Royalties.**", "**Royalty Period.**", "**SCHEDULE 1.13**", "**SCHEDULE 1.53**", "**SCHEDULE 4.05**", "**Sales Milestone Event**", "**Sales Milestone Payment**", "**Sales Milestones.**", "**Schedule 1.13**", "**Schedule 1.53**", "**Schedule 4.05**", "**Schedules.**", "**Severability.**", "**Term of the Option.**", "**Term.**", "**Termination for Failure to Meet Key Development Milestones**", "**Termination for Insolvency/Bankruptcy.**", "**Third Party Infringement Actions.**", "**Trademarks.**", "**Transfer of Know-How.**", "**Voluntary Termination by PII.**", "**WITNESSETH THAT:**", "**Waiver.**", "**Warranties by PII.**", "**Warranties by RBX.**", "**[*", "**\u201cDevelopment\u201d**", "**\u201cGAAP\u201d**", "**\u201cJoint Invention\u201d**", "**\u201cJoint Patents\u201d**", "*]      [*", "*] dollars ($[*", "*] per occurrence (or claim) and an annual aggregate of **", "*] that are in RBX\u2019s possession as of the Effective Date (\u201cRBX [*", "*] totaling approximately [*", "*]**", "*]. PII will notify RBX in writing upon Completion of the **", "*]. PII will notify RBX in writing upon the Completion of the **", "*except*", "\u201c**Force Majeure\u201d**", "\u201c**Option Period**\u201d", "\u201c**Option Termination Date**\u201d", "\u201c**Option**\u201d", "\u201cAAA\u201d", "\u201cAgreement\u201d", "\u201cAlliance Manager\u201d", "\u201cClaim\u201d", "\u201cDMF\u201d", "\u201cDefaulting Party\u201d", "\u201cEffective Date\u201d", "\u201cIndemnifying Party\u201d", "\u201cJoint Invention\u201d", "\u201cJoint Patent Rights\u201d", "\u201cJoint Patents\u201d", "\u201cLicense Fee\u201d", "\u201cMajor Regulatory Filings\u201d", "\u201cMilestone Payment\u201d and collectively the \u201cMilestone Payments\u201d", "\u201cNon-Defaulting Party\u201d", "\u201cOption Period\u201d", "\u201cOption\u201d", "\u201cPII Patents\u201d", "\u201cPPD\u201d", "\u201cParagraph IV Challenge\u201d and collectively with an Infringement Action, \u201cSection 8.03 Actions\u201d", "\u201cRBX [*]\u201d", "\u201cRBX\u201d", "\u201cResearcher\u201d", "\u201calleged infringement\u201d"]}}